With indebted blessings of the Almighty God , I would like to inform our readers that our journal IJDMS has successfully completed its one year. On the occasion of our journal's Anniversary, I take this opportunity to express my profound gratitude to our managing editors, all of the Editorial board members, reviewers, readers and most importantly our publisher Renu Publishers for their constant support and untiring efforts in this endeavour of ours. I wish the journal reaches new heights.
Adverse drug reactions cause a significant amount of mortality and morbidity worldwide. The domain of pharmacovigilance made an enormous impact since it was recognized after the thalidomide disaster in the early 1960s, which resulted in foetal abnormalities. It was followed by the withdrawal of rofecoxib that renewed the interest in drug safety mechanisms. Pharmacovigilance, according to World Health Organization 2002, is defined as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem." [1] It plays a significant role in assuring that patients receive safe drugs. The objective of pharmacovigilance is to ensure patient care and safety related to medication. Lately, this field of drug safety has received a lot of recognition.
Pharmacovigilance is, in essence, the steps and procedure of monitoring the everyday use of essential medicines to identify and diagnosed previously unrecognized adverse drug reactions (ADRs), thereby assessing their risk/benefit balance in order to determine what action, if any, is necessary to improve their safe use. As a discipline, pharmacovigilance impacts on many specialist areas such as pharmacoepidemiology, medical practice, public health, but is most intimately linked to clinical research, development and drug licensing. In the end, I would like to conclude by stating that the shear motive of this editorial is to make our readers aware regarding the importance of drug safety in our lives. The pharmacovigilance of tomorrow should be raised to a level such that the new safety issues are identified without delay and should be able to tell which patients are at a risk of developing ADRs.
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